Exact Sciences to Participate in November Investor Conference

Audio By Carbonatix

MADISON, Wis.--(BUSINESS WIRE)--Nov 4, 2025--

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

• Jefferies London Healthcare Conference, London
  Fireside chat on Tuesday, November 18, 2025 at 7:30 a.m. ET (12:30 p.m. GMT)

The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences (Nasdaq: EXAS) helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company’s growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like the Cancerguard® test for multi-cancer early detection and the Oncodetect® test for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow @ExactSciences on X, or connect on LinkedIn and Facebook.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251104173305/en/

CONTACT: Derek Leckow

Exact Sciences Corp.

[email protected]

608-893-0009

KEYWORD: UNITED STATES NORTH AMERICA WISCONSIN

INDUSTRY KEYWORD: RESEARCH MEDICAL DEVICES MEDICAL SUPPLIES OTHER HEALTH HEALTH GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY

SOURCE: Exact Sciences Corp.

Copyright Business Wire 2025.

PUB: 11/04/2025 07:00 AM/DISC: 11/04/2025 07:00 AM

http://www.businesswire.com/news/home/20251104173305/en